Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder.
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
Raxone®/Catena® (idebenone)
Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
In vivo time-lapse imaging shows dynamic oligodendrocyte progenitor behavior during zebrafish development.
Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders.
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.
Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models.
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
Antioxidant properties of the triaminopyridine, flupirtine.
The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria.
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.
Comparative miRNA-Based Fingerprinting Reveals Biological Differences in Human Olfactory Mucosa- and Bone-Marrow-Derived Mesenchymal Stromal Cells.
Keystone Symposium: Multiple Sclerosis
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Rituximab product approval information - Licensing action
Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.

Pages